

Anti-INI-1

Catalog No.	Description
AMB02-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AMB02-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
MUB02-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
MUB02-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AXB02-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 160 tests
AXB02-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 50 tests
AXB02-4M	Ready-to-Use Antibody in Barcode labeled vial for use on the NanoVIP® Staining System, 50 tests
VMB02-5M	6 ml of Ready-to-Use Antibody for use with BioGenex / equivalent Detection systems on third party automation.

Clone	Species	Ig Class
A-5	Mouse	IgG1

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of human INI-1 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Integrase interactor 1 (INI-1), also known as hSNF5, is an integral component of the hSWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling complex, which facilitates DNA dependent cellular processes including transcription, replication, and repair. The INI-1 gene is often mutated or deleted in malignant rhabdoid tumor (MRT), a tumor which is potentially mimicked by medulloblastoma and supratentorial primitive neuroectodermal tumors (sPNETs). The morphology of MRTs can present challenges in differential diagnosis. The overall survival of MRTs relative to its potential mimics [medulloblastoma, supratentorial primitive neuroectodermal tumors (sPNETs)] is quite low, and thus differentiation from these other tumors is desirable. INI-1 has shown to be useful in distinguishing between the three conditions as the majority of medulloblastomas and sPNETs are labeled by Anti-INI-1, while

a lack of nuclear labeling by the same antibody is characteristic of MRT.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The [primary antibody](#) may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody to human INI-1 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	Renal cell carcinoma tissue as available with Biogenex FB-B02M* & FG-B02M*
Recommended Dilution for Concentrated Antibody	1:50-100 in HK941
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended Pretreatment (Xmatrx & NanoVIP)	EZ-AR2 Elegance (HX032-YCD & HX046-08XN)
Antibody Incubation (Manual/i6000)	30-60 Min at RT
Antibody Incubation (Xmatrx & NanoVIP)	30-60 Min at 25°C

Category	Antibodies	Revision No.	D
Document No.	932-B02M-EN	Release Date	16-Apr-2024

Detection System for Manual, Xmatrx, NanoVIP & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information
---	--

*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx & NanoVIP requires micro chamber slides.

**Pretreatment times will vary based on individual microwave power.

***For automation systems (Xmatrx-Elite, NanoVIP & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKEN (1000 Test)		
	QD420-YIKEN (500 Test)	QD620-XAKEN (500 Test)	QP900-9LE (500 Test)
	QD400-60KEN (60 Test)		
Xmatrx - Automation	QD550-YCDEN (200 Test)	QD610-YADEN (200 Test)	N/A
NanoVIP- Automation	QD551-YCDEN (100 Test)	QD611-YADEN (100 Test)	N/A
i6000 - Automation	QD410-YAXEN (200 Test)	QD610-YAXEN (200 Test)	N/A
For more information, visit www.biogenex.com .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains nucleus in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Muchardt, C., et al. 1993. A human homologue of *Saccharomyces cerevisiae* SNF2/SWI2 and *Drosophila* Brm genes potentiates transcriptional activation by the glucocorticoid receptor. *EMBO J.* 12: 4279-4290.
- Khavari, P.A., et al. 1993. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. *Nature* 366: 170-174.
- Tsukiyama, T., et al. 1995. ISWI, a member of the SWI2/SNF2 ATPase family, encodes the 140 kDa subunit of the nucleosome remodeling factor. *Cell* 83: 1021-1026.

	Temperature Limitation		In Vitro Diagnostic Medical Device
	Use By Date		Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	D
Document No.	932-B02M-EN	Release Date	16-Apr-2024